# A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

> **NCT05849662** · PHASE1,PHASE2 · RECRUITING · sponsor: **Therapeutic Advances in Childhood Leukemia Consortium** · enrollment: 58 (estimated)

## Conditions studied

- Leukemia, Juvenile Myelomonocytic
- JMML
- JCML
- Neurofibromatosis 1
- CBL Syndrome

## Interventions

- **DRUG:** Trametinib
- **DRUG:** Azacitidine
- **DRUG:** Fludarabine
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT05849662
- **Lead sponsor:** Therapeutic Advances in Childhood Leukemia Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-11
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05849662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05849662, "A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05849662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*